Substantial Amendment 07 Back to 'For participating sites' SA07 MHRA Cover Letter v1.0, 12-Dec-2016 [pdf] SA07 MHRA Acknowledgement of Amendment 16-Dec-2016 [pdf] SA07 MHRA Acceptance of Amendment 16-Jan-2017 [pdf] SA07 REC Cover Letter v1.0, 12-Dec-2016 [pdf] SA07 REC Acknowledgment of Substantial Amendment 13-Dec-2016 [pdf] SA07 REC Favourable Opinion Letter 03-Jan-2017 [pdf] SA07 HRA Confirmation of REC Validation and Categorisation of Amendment 13-Dec-2016 [pdf] SA07 HRA Confirmation of Amendment Assessment 23-Jan-2017 [pdf] SA07 Summary of Protocol v4.0 Changes v1.0, 12-Dec-2016 [pdf] SA07 Summary of Patient Document Changes v1.0 ,25-Nov-2016 [pdf] Trial Protocol v4.0, 12-Dec-2016 [pdf] Trial Protocol Synopsis v4.0, 12-Dec-2016 [pdf] Pharmacy Manual v4.0, 24-Jan-2017 [pdf] Laboratory Manual v4.0 [pdf] Arm A: Addendum A - Patient Information Sheet & Informed Consent Form v1.0, 24-Nov-2016 [doc] Arm B: Addendum A - Patient Information Sheet & Informed Consent Form v1.0, 24-Nov-2016 [doc] Arm C: Addendum A - Patient Information Sheet & Informed Consent Form v1.0, 24-Nov-2016 [doc] Arm D: Addendum A - Patient Information Sheet & Informed Consent Form v1.0, 24-Nov-2016 [doc] Arm E: Addendum A - Patient Information Sheet & Informed Consent Form v1.0, 24-Nov-2016 [doc] Arm F: Addendum A - Patient Information Sheet & Informed Consent Form v1.0, 24-Nov-2016 [doc] Arm G: Addendum A - Patient Information Sheet & Informed Consent Form v1.0, 24-Nov-2016 [doc] Arm NA, Cohort NA1: Addendum A - Patient Information Sheet & Informed Consent Form v1.0, 24-Nov-2016 [doc] Arm A: AZD4547 – Patient Information Sheet & Informed Consent Form v5.0, 24-Nov-2016 [doc] Arm B: Vistusertib – Patient Information Sheet & Informed Consent Form v5.0, 24-Nov-2016 [doc] Arm C: Palbociclib – Patient Information Sheet & Informed Consent Form v5.0, 24-Nov-2016 [doc] Arm D: Crizotinib – Patient Information Sheet & Informed Consent Form v5.0, 24-Nov-2016 [doc] Arm E: Selumetinib & Docetaxel – Patient Information Sheet & Informed Consent Form v5.0, 24-Nov-2016 [doc] Arm F: AZD5363 – Patient Information Sheet & Informed Consent Form v2.0, 24-Nov-2016 [doc] Arm G: Osimertinib – Patient Information Sheet & Informed Consent Form v2.0, 24-Nov-2016 [doc] Arm NA Cohort NA1: Durvalumab – Patient Information Sheet & Informed Consent Form v5.0, 24-Nov-2016 [doc] Biopsy for Molecular Testing – Patient Information Sheet & Informed Consent Form v5.0, 24-Nov-2016 [doc] Pre-Trial Research Biopsy – Patient Information Sheet & Informed Consent Form v5.0, 24-Nov-2016 [doc] Post-Trial Research Biopsy – Patient Information Sheet & Informed Consent Form v5.0, 24-Nov-2016 [doc] Arm A: AZD4547 – GP Letter v5.0, 24-Nov-2016 [doc] Arm B: Vistusertib – GP Letter v5.0, 24-Nov-2016 [doc] Arm C: Palbociclib – GP Letter v5.0, 24-Nov-2016 [doc] Arm D: Crizotinib – GP Letter v5.0, 24-Nov-2016 [doc] Arm E: Selumetinib & Docetaxel – GP Letter v5.0, 24-Nov-2016 [doc] Arm F: AZD5363 – GP Letter v2.0, 24-Nov-2016 [doc] Arm G: Osimertinib – GP Letter v2.0, 24-Nov-2016 [doc] Arm NA Cohort NA1: Durvalumab – GP Letter v5.0, 24-Nov-2016 [doc] Arm A: AZD4547 – Patient Diary v3.0, 24-Nov-2016 [pdf] Arm B: Vistusertib – Patient Diary v3.0, 24-Nov-2016 [pdf] Arm C: Palbociclib – Patient Diary v3.0, 24-Nov-2016 [pdf] Arm D: Crizotinib – Patient Diary v3.0, 24-Nov-2016 [pdf] Arm E: Selumetinib – Patient Diary v3.0, 24-Nov-2016 [pdf] Arm F: AZD5363 – Patient Diary v2.0, 24-Nov-2016 [pdf] Arm G: Osimertinib – Patient Diary v2.0, 24-Nov-2016 [pdf] Release of Medical Information Form v3.0, 24-Nov-2016 [doc] Patient ID Card v2.0, 24-Nov-2016 [pdf] Registration Form v4.0, 24-Jan-2017 [pdf] Core Eligibility Checklist v3.0, 24-Jan-2017 [pdf] Eligibility Checklist - Arm A AZD4547 v4.0, 23-Jan-2017 [pdf] Eligibility Checklist – Arm B Vistusertib v3.0, 24-Jan-2017 [pdf] Eligibility Checklist – Arm C Palbociclib v5.0, 24-Jan-2017 [pdf] Eligibility Checklist – Arm D Crizotinib v4.0, 24-Jan-2017 [pdf] Eligibility Checklist – Arm E Sel & Doc v3.0, 24-Jan-2017 [pdf] Eligibility Checklist – Arm F AZD5363 v2.0, 24-Jan-2017 [pdf] Eligibility Checklist – NA Cohort NA1 Durvalumab v5.0, 24-Jan-2017 [pdf]